TOWARD, A Metabolic Health Intervention, Demonstrates Robust 1 Year Weight Loss And Cost Savings Through Deprescription

Researchers studied a comprehensive metabolic health program called TOWARD that was offered to 50 employees at a manufacturing company. The participants had an average BMI of 43 (indicating obesity) and 64% had prediabetes or type 2 diabetes. The program combined several approaches delivered through telemedicine: text-based support, online interactions, wellness coaching, educational materials, remote monitoring of health metrics, and dietary changes that emphasized reducing carbohydrate intake.

After one year, the results were striking. The 50 participants lost an average of 43 pounds (19.5 kg), representing 15.5% of their total body weight. Even more importantly, they were able to stop taking 96 medications while only starting 8 new ones - a process called "deprescription" that indicates their health conditions were improving enough to require less pharmaceutical intervention. Participants who had been taking expensive GLP-1 medications (like Ozempic or Wegovy) were able to discontinue them while maintaining or continuing their weight loss.

The financial impact was significant as well. The TOWARD program saved approximately $1,700 per patient annually, compared to GLP-1 medications which cost about $13,000 per patient per year. This suggests that intensive lifestyle interventions focusing on carbohydrate reduction can be both more effective and more cost-efficient than relying primarily on medications for metabolic health issues.

This research demonstrates that comprehensive lifestyle programs can achieve results comparable to expensive medications while actually improving overall health enough to reduce medication dependence. For patients interested in metabolic health, this supports the potential of structured low-carb approaches combined with coaching and monitoring as a viable alternative or complement to pharmaceutical treatments, particularly when delivered through accessible telemedicine platforms.